JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Asperen, J.
Right arrow Articles by Beijnen, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Asperen, J.
Right arrow Articles by Beijnen, J. H.

Vol. 289, Issue 1, 329-333, April 1999

Comparative Pharmacokinetics of Vinblastine after a 96-Hour Continuous Infusion in Wild-Type Mice and Mice Lacking mdr1a P-Glycoprotein1

Judith van Asperen2 , Olaf van Tellingen, Alfred H. Schinkel and Jos H. Beijnen

Departments of Clinical Chemistry (J.v.A., O.v.T.) and Experimental Therapy (A.H.S.), the Netherlands Cancer Institute, Amsterdam, the Netherlands; and Department of Pharmacy, Slotervaart Hospital, Amsterdam, the Netherlands (J.H.B.)

To determine the tissue-specific impact of P-glycoprotein on the accumulation of a substrate drug, we have studied the tissue distribution of vinblastine in mdr1a(-/-) and wild-type mice at approximately similar, relatively low plasma levels. Vinblastine was administered as a 96-h continuous infusion at dose rates of 1 to 10 µg/h, which were delivered by a s.c.-implanted osmotic pump. Drug concentrations were determined in plasma and tissues by HPLC. In comparison to wild-type mice, 4.4- to 9.6-fold higher drug concentrations were observed in the brains of mdr1a(-/-) mice (p <=  .014), whereas a 2-fold increase was found in the heart (p = .014) and the intestinal tissues (p <=  .028). No or only slight differences were observed in all other tissues. These results indicate that, except for the brain and, to a lesser extent, the heart and the intestinal tissues, P-glycoprotein does not protect individual organs against vinblastine. Given its polarized cell-specific and organ-specific distribution and its affinity for a broad range of compounds, it is suggested that P-glycoprotein has mainly evolved to provide a general protection of the complete organism against potentially toxic substrates by inhibiting their uptake and by mediating their transport from the internal to the external environment. For the clinical application of reversal agents, these data indicate that, in general, a blockade of endogenous P-glycoprotein will probably not result in an increased accumulation of the coadministered anticancer drug in complete organs, but, possibly, only in classes of cells making up a fraction of an organ.


0022-3565/99/2891-0329$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Davis
Gender Differences in p-Glycoprotein: Drug Toxicity and Response
J. Clin. Oncol., September 10, 2005; 23(26): 6439 - 6440.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. S. Cox, K. R. Scott, H. Gao, and N. D. Eddington
Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological Approaches
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1096 - 1104.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Weiss and W. Kang
P-Glycoprotein Inhibitors Enhance Saturable Uptake of Idarubicin in Rat Heart: Pharmacokinetic/Pharmacodynamic Modeling
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 688 - 694.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.